MedTrace Logo

Magnetic Resonance-Guided High Intensity Focused Ultrasound for Recurrent Rectal Cancer

NCT02528175 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-12-07

No results posted yet for this study

Summary

This pilot study hypothesizes that hyperthermia delivered via magnetic resonance-guided focused ultrasound (MRg-FU) is technically feasible and can be safely used in combination with concurrent reirradiation and chemotherapy for the treatment of recurrent rectal cancer. Twenty recurrent rectal cancer patients who are not candidates for surgery will be recruited for hyperthermia treatment delivered via MRg-FU concurrent with reirradiation and oral chemotherapy.

Conditions

  • Recurrent Rectal Cancer

Interventions

DEVICE

Magnetic resonance-guided focused ultrasound

Targeted warming of the tumor via 3 weekly MR-guided ultrasound procedures. Concurrent with radiation and chemotherapy.

RADIATION

Standard Radiation

30.6 Gray (Gy) over 17 fractions concurrent with chemotherapy (institutional standard).

DRUG

Chemotherapy

3.5 weeks concurrent with radiation therapy (institutional standard).

Sponsors & Collaborators

  • Philips Medical Systems

    collaborator INDUSTRY

  • William Chu, MD, MSc, FRCPC

    lead OTHER

Principal Investigators

  • William Chu, MD, FRCPC · Sunnybrook Health Sciences Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2021-04-30
Completion
2022-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02528175 on ClinicalTrials.gov